1Bai XY,Miao D,Goltzman D,et al. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem, 2003,278: 9843-9849.
2Shimada T, Muto T, Urakawa I, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology, 2002,143:3179-3182.
3Nesbitt T, Coffman TM, Griffitha R,et al. Crosstransplantation of kidneys in normsl and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J Clin Invest, 1992,89: 1453-1459.
4Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type Ⅱ a. Biochem Biophys Res Commun,2004,314:409-414.
5Jan de Beur SM, Levine MA. Molecular pathogenesis of hypophosphatemic rickets. J Clin Endocrinol Metab,2002,87:2467-2473.
6Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF-23 as a causative factor of tumor induced osteomalacia. Proc Natl Acad Sci USA,2001,98:6500-6505.
7White KE, .Jonsson KB, Carn G, et al. The ADHR gene is a secreted polypeptide over-expressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab,2001,86:497-500.
8The ADHR Consortium. Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF-23. Nat Genet, 2000,26: 345-348.
9Jonnson KB, Zahraadnik R, Larsson T, et al. Fibroblast growth factor 23in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med,2003,348:1656-1663.
10Yamazaki Y,Okazaki R,Shibota M,et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab, 2002,87:4957-4960.
